To combat this, significant attempts have been made to modify the CAR constructs in solid tumors like melanoma by blocking the activation of inhibitory immune checkpoint receptors on T cells, with the most common of these receptors being PD-1 and CLTA-4. Here, PDCD1 is linked to melanoma.